20.500.12556/DiRROS-18510 Effects of electrochemotherapy on immunologically important modifications in tumor cells Electrochemotherapy (ECT) is a clinically acknowledged method that combines the use of anticancer drugs and electrical pulses. Electrochemotherapy with bleomycin (BLM) can induce immunogenic cell death (ICD) in certain settings. However, whether this is ubiquitous over different cancer types and for other clinically relevant chemotherapeutics used with electrochemotherapy is unknown. Here, we evaluated in vitro in the B16-F10, 4T1 and CT26 murine tumor cell lines, the electrochemotherapy triggered changes in the ICD-associated damage-associated molecular patterns (DAMPs): Calreticulin (CRT), ATP, High Mobility Group Box 1 (HMGB1), and four immunologically important cellular markers: MHCI, MHC II, PD-L1 and CD40. The changes in these markers were investigated in time up to 48 h after ECT. We showed that electrochemotherapy with all three tested chemotherapeutics induced ICD-associated DAMPs, but the induced DAMP signature was cell line and chemotherapeutic concentration specific. Similarly, electrochemotherapy with CDDP, OXA or BLM modified the expression of MHC I, MHC II, PD-L1 and CD40. The potential of electrochemotherapy to change their expression was also cell line and chemotherapeutic concentration specific. Our results thus put the electrochemotherapy with clinically relevant chemotherapeutics CDDP, OXA and BLM on the map of ICD inducing therapies. electrochemotherapy cisplatin immune response elektrokemoterapija cisplatin imunski odgovor true false true MDPI Basel, Switzerland Angleški jezik Slovenski jezik by Authors Neznano 2024-03-21 09:24:01 2024-03-21 09:24:01 2024-03-22 03:48:33 0000-00-00 00:00:00 2023 0 0 Nasl. z nasl. zaslona; Opis vira z dne 9. 5. 2023; str. 925-1-925-22 no. 5 Vol. 11 2023 0000-00-00 Zaloznikova Objavljeno apc 2023-03-31 2023-04-27 2023-04-30 602 2076-393X 10.3390/vaccines11050925 151344131 https://www.mdpi.com/2076-393X/11/5/925 1 60232214-e75c-11ee-9dd4-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25221 RAZ_Kesar_Ursa_2023.pdf RAZ_Kesar_Ursa_2023.pdf 1 43961FF3470868C06D61B106DF01FCD7 2a8b40b256be069de4d9e604113650b5ceeedc03a3767cc55f949555fb5ec674 f9f43993-e75c-11ee-9dd4-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25222 Onkološki inštitut Ljubljana 0 0 0